Biocon sells 5.4% stake in arm Syngene International for Rs 1,220 cr

Drugmaker Biocon divested a 5.4% stake in its research arm Syngene International for a little over Rs 1,220 crore through an open market transaction

Syngene International's Bangalore facility
Syngene International's Bangalore facility
Press Trust of India New Delhi
2 min read Last Updated : Sep 06 2022 | 11:38 PM IST

Drugmaker Biocon on Tuesday divested a 5.4 per cent stake in its research arm Syngene International for a little over Rs 1,220 crore through an open market transaction.

According to bulk deal data available with the BSE, Biocon, the promoter of Syngene International, sold a total of 21,789,164 shares, amounting to a 5.4 per cent stake, in the company.

The shares were sold at an average price of Rs 560.04 apiece, a discount of more than three per cent to Monday's closing price of Rs 578.75 on the BSE.

At this price, the transaction size has been pegged at Rs 1,220.28 crore, the data showed.

The scrip of Syngene International has settled 2.38 per cent lower at Rs 565 apiece on the BSE.

ICICI Prudential Mutual Fund was among the entities that lapped up the company's shares.

As of June year, of the promoters' holding of 70.29 per cent, Biocon held a 69.99 per cent stake in Syngene, the shareholding pattern with the exchange showed.

In separate block deals, Raja Ganesan Chandramogan, promoter of Hatsun Agro Products, offloaded 27.2 lakh shares of the company for nearly Rs 269 crore.

The shares were picked up by Sundaram Mutual Fund and SBI Mutual Fund.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Syngene InternationalBiocon

First Published: Sep 06 2022 | 8:16 PM IST

Next Story